In this episode, Liza O'Dowd, MD, discusses the 52-week data from the ICONIC clinical program of icotrokinra, the most recently approved oral peptide agent for psoriasis.
Liza O'Dowd, MD
Advertisement
Dr O’Dowd is vice president and immunodermatology and respiratory disease areas lead at Johnson & Johnson.
Articles by Liza O'Dowd, MD
Liza O'Dowd, MD, discusses the drug's long road to FDA approval and what its oral delivery means for patients with plaque psoriasis.
Liza O'Dowd, MD, shared insights on the latest data on icotrokinra at the AAD Annual Meeting.
Advertisement
